Opus Genetics (NASDAQ:IRD) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Opus Genetics (NASDAQ:IRD) to a strong-buy rating in a research report report published on Thursday,Zacks.com reports.

Several other research firms also recently commented on IRD. Brookline Capital Acquisition upgraded shares of Opus Genetics to a “strong-buy” rating in a research note on Monday, December 1st. BTIG Research reaffirmed a “buy” rating and set a $7.00 price target on shares of Opus Genetics in a research report on Wednesday, January 28th. Wall Street Zen raised Opus Genetics from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, January 22nd. Finally, Piper Sandler initiated coverage on Opus Genetics in a research report on Tuesday, November 25th. They issued an “overweight” rating and a $7.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $7.75.

Opus Genetics Price Performance

Shares of NASDAQ IRD opened at $3.64 on Thursday. Opus Genetics has a fifty-two week low of $0.65 and a fifty-two week high of $3.70. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.23 and a current ratio of 1.23. The company has a market cap of $251.01 million, a PE ratio of -1.94 and a beta of 0.58. The business has a 50-day simple moving average of $2.36 and a two-hundred day simple moving average of $1.90.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. Opus Genetics had a negative net margin of 466.09% and a negative return on equity of 697.94%. The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $3.07 million. As a group, equities analysts expect that Opus Genetics will post -1.22 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Fighting Blindness Foundation sold 4,000,000 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $2.15, for a total transaction of $8,600,000.00. Following the sale, the director directly owned 5,492,171 shares of the company’s stock, valued at $11,808,167.65. This represents a 42.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Cam Gallagher bought 83,000 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were acquired at an average price of $1.97 per share, for a total transaction of $163,510.00. Following the completion of the transaction, the director directly owned 83,000 shares in the company, valued at approximately $163,510. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 6.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Opus Genetics

A number of large investors have recently bought and sold shares of IRD. Comerica Bank acquired a new stake in Opus Genetics in the first quarter valued at approximately $29,000. Raymond James Financial Inc. lifted its position in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after buying an additional 11,000 shares in the last quarter. Johnson Investment Counsel Inc. acquired a new stake in Opus Genetics in the 4th quarter valued at $40,000. Regency Capital Management Inc. DE purchased a new stake in Opus Genetics in the 4th quarter worth $92,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new position in Opus Genetics during the fourth quarter worth $157,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Lifesci Capital upgraded IRD to “Strong‑Buy” and published more constructive estimates (quarterly EPS in the ~($0.11)–($0.13) range and FY2026 forecast of ~($0.48)), signaling an expectation of improving losses versus the deeper consensus loss. This analyst endorsement likely boosted investor confidence in the story and outlook.
• Positive Sentiment: Opus announced a $25.0M private placement of 7,374,632 shares of Series B Non‑Voting Convertible Preferred Stock at $3.39 per share, which provides immediate non‑dilutive cash for operations and clinical development and reduces near‑term funding risk. Article Title
• Neutral Sentiment: Media coverage (including Zacks/MSN headlines) amplified the newsflow, increasing attention and trading activity in IRD shares without changing fundamentals by itself. Article Title
• Negative Sentiment: The private placement is convertible preferred stock, so conversion into common shares would be dilutive to existing common shareholders; the $3.39 issuance price is a modest discount to recent trading, which can exert downward pressure on the common share price over time if conversions or resale occur. Article Title

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.